Integrated Health Concepts Inc.
Letter data
- Company
- Integrated Health Concepts Inc.
- Recipient
- Taylor Cline | Chief Executive Officer and President | Integrated Health Concepts Inc. | 720 Aerovista Place | Suite D | San Luis Obispo | , | CA | 93401-8726 | United States
- Issue date
- 2022-01-18
- Posted date
- Not available
- FDA office
- Division of Pharmaceutical Quality Operations IV
- Subject
- Not available
- Product
- Drugs
- CMS ID
- 610546
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Integrated Health Concepts Inc.
MARCS-CMS 610546 —
January 18, 2022
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
VIA EMAIL CONFIRMED DELIVERY
Product:
Drugs
Recipient:
Recipient Name
Taylor Cline
Recipient Title
Chief Executive Officer and President
Integrated Health Concepts Inc.
720 Aerovista Place
Suite D
San Luis Obispo
,
CA
93401-8726
United States
Issuing Office:
Division of Pharmaceutical Quality Operations IV
United States
Dear Mr. Taylor Cline:
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL 610546) dated September 10, 2020. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV
Content current as of:
02/02/2022
Regulated Product(s)
Drugs